Story
UBS Initiates Medtech Coverage, Taps Intuitive Surgical and Enovis as Buys
UBS initiated coverage on a group of U.S. medical technology companies on Monday, issuing favorable Buy ratings for robotic surgery leader Intuitive Surgical and orthopedic device maker Enovis. The firm took a more cautious or negative stance on others in the sector, highlighting a selective approach based on innovation and market expansion.
Bullish on Robotics and Orthopedics
In a note to clients, UBS stated that while the medtech sector offers opportunities from procedure growth and innovation, investors should be selective. The firm's most positive outlook was on Intuitive Surgical (ISRG), which it started with a Buy rating and a $500 price target.
UBS analysts believe investor concerns over automation risks and market saturation are overstated. The firm argued automation could accelerate the adoption of robotic surgery and projected a five-year revenue compound annual growth rate (CAGR) of about 15% for the company, citing opportunities in cardiac and endoluminal procedures.
Enovis (ENOV) also received a Buy rating with a $51 price target. UBS pointed to improving fundamentals following the integration of LimaCorporate, with management now shifting focus to organic growth. The firm highlighted new product launches and its ARVIS augmented reality platform, which it sees as a potential lower-cost alternative to full robotic systems.
AdCautious Outlook on Inspire and Integra
Conversely, UBS initiated coverage of Inspire Medical Systems (INSP) with a Sell rating and a $39 price target. According to the note, the company's slowing growth reflects "deeper structural challenges," including rising competition and uncertainty around reimbursement for its obstructive sleep apnea therapy. UBS believes consensus sales forecasts for the company are "too optimistic."
Integra LifeSciences (IART) received a Neutral rating and a $19 price target. While UBS acknowledged the company's leadership in neurosurgery and wound care, it concluded that the shares already reflect a stable growth trajectory. The firm sees "limited near-term catalysts" to drive a significant re-rating of the stock.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.